OBJECTIVE - Youth with diabetes are at increased risk for depression. The objectives of this study were to provide preliminary evidence that this at-risk status for depression is associated with metabolic and inflammatory markers and to inform future, more

A fast (≤0.1 ms) and compact 'multi-colour' soft x-ray array has been developed for time and space-resolved electron temperature (Te) measurements in magnetically confined fusion (MCF) plasmas. The electron temperature is obtained by modelling the slope of the continuum radiation from ratios of the available 1D-Abel inverted radial emissivity profiles over different energy ranges, with no a priori assumptions of plasma profiles, magnetic field reconstruction constraints or need of shot-to-shot reproducibility. This technique has been used to perform fast Te measurements in the National Spherical Torus Experiment (NSTX), avoiding the limitations imposed by the well-known multi-point Thompson scattering, electron cyclotron emission and electron Bernstein wave mode conversion diagnostics. The applicability of this 'multi-colour' technique for magnetohydrodynamic (MHD) mode recognition and a variety of perturbative electron and impurity transport studies in MCF plasmas is also discussed. Reconstructed 'multi-colour' emissivity profiles for a variety of NSTX scenarios are presented here for the first time. © 2007 IOP Publishing Ltd.

The development of noninductive current drive is of great importance in establishing the tokamak as a long-pulse or steady-state fusion reactor. Lower hybrid waves, carrying 200 kW of power at 800 MHz, have been launched into the Princeton Large Torus tokamak to initiate and drive the discharge current to a level in excess of 100 kA. © 1984 The American Physical Society.

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab - for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians' understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S.

Routine tritium operation in TFTR has permitted investigations of alpha particle physics in parameter ranges resembling those of a reactor core. ICRF wave physics in a DT plasma and the influence of isotopic mass on supershot confinement have also been studied. Continued progress has been made in optimizing fusion power production in TFTR, using extended machine capability and Li wall conditioning. Performance is currently limited by MHD stability. A new reversed magnetic shear regime is being investigated with reduced core transport and a higher predicted stability limit.

Three campaigns, prior to July 1994, attempted to increase the fusion power in DT plasmas on the Tokamak Fusion Test Reactor (TFTR). The first campaign was dedicated to obtaining >5 MW of fusion power while avoiding MHD events similar to the JET X-event. The second was aimed at producing maximum fusion power irrespective of proximity to MHD limits, and achieved 9 MW limited by a disruption. The third campaign increased the energy confinement time using lithium pellet conditioning while raising the ratio of alpha heating to beam heating.